Lundbeck research enhances understanding of Alzheimer’s

Biological hypothesis behind our antibody treatment is confirmed in major step forward for the project.

Researchers at Lundbeck has made new discoveries of the earliest pivotal biological processes in the brain leading to Alzheimer’s disease (Alzheimer’s). This may pave the way for new and better treatments like the antibody treatment that Lundbeck hopes to take into clinical development in 1-2 years’ time.

Our antibody targets and stops the spreading of tangles of the protein tau, which is one of two causes of Alzheimer’s (the aggregation of plaques of the protein a-beta being the other). The hope is that the antibody will therefore be able to stop or delay the progression of the disease.

As part of the research work, Lundbeck has created a three-dimensional structure – a picture on atomic level, so to speak – of exactly where the antibody binds in the brain. The research has revealed that a certain chemical process taking place right here is what causes the progression of Alzheimers. This also confirms the hypothesis behind our tau antibody and improves the probability that it will indeed be able to halt or stop the progression of the disease.

The new research has been conducted in close collaboration with the research group led by professor Einar Sigurdsson at New York University. The results, recently published in the recognized publication Nature Scientific Reports, are another testament to the value of our strategy of partnering with leading experts in research.

Alzheimer's disease

Alzheimer’s disease is a neurological disorder in which the brain slowly degenerates, leading to problems with memory, daily function and behaviour.

 

Learn more

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.